SRR and Alzheimer disease: In conclusion, using in silico docking and in vitro screening, we identified NSC294149 (2-amino-3-(3-nitroimidazo[1,2-a]pyridin-2-yl)sulfanylpropanoic acid) as a potential SRR agonist, and its treatment on AD Drosophila improved the hazard ratio of survival and motor function.